Evaluation of the Implementation and Effectiveness of IPP-HPV
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 15 - 26 |
| Updated: | 1/11/2018 |
| Start Date: | January 2017 |
| End Date: | March 2019 |
| Contact: | Sangini Sheth, MD |
| Email: | eugene.shapiro@yale.edu |
| Phone: | +1 (203) 688-4555 |
Evaluation of the Implementation and Effectiveness of a Pilot Quality Improvement Program to Increase HPV Vaccine Uptake: Inpatient Postpartum HPV Immunization (IPP-HPV) Program
The purpose of the proposed pilot study is to assess the implementation of IPP-HPV
immunization at Yale New Haven Hospital (YNHH) and to identify potential barriers to and
facilitators of this intervention to optimize its feasibility and effectiveness. It is
imperative that innovative interventions be developed to achieve comprehensive utilization of
this highly effective vaccine to reduce rates of HPV infection, lower rates of cervical and
other HPV associated cancers, and address cancer disparities.
immunization at Yale New Haven Hospital (YNHH) and to identify potential barriers to and
facilitators of this intervention to optimize its feasibility and effectiveness. It is
imperative that innovative interventions be developed to achieve comprehensive utilization of
this highly effective vaccine to reduce rates of HPV infection, lower rates of cervical and
other HPV associated cancers, and address cancer disparities.
Administration of the HPV vaccine during the inpatient postpartum hospital stay has the
potential to be an innovative intervention to improve HPV immunization rates. Following onset
of pregnancy, the postpartum period becomes the next available opportunity to immunize with
the HPV vaccine, which is safe in breastfeeding women. The benefits of such an intervention
include a focus on women engaged with the health care system who are often highly motivated
to invest in their personal health.
Specific Aims Aim 1: To evaluate receptivity and concerns of postpartum women with receiving
the HPV vaccine during the inpatient postpartum admission as part of the Inpatient Postpartum
HPV Immunization Quality Improvement Program (IPP-HPV).
Aim 2: To evaluate receptivity and concerns of healthcare providers with inpatient postpartum
HPV immunization as part of IPP-HPV and to identify facilitators of and barriers to its
implementation.
Aim 3: To assess the uptake and effectiveness of a Pilot Quality Improvement Program to
increase HPV vaccine uptake (IPP-HPV) for Yale New Haven Hospital (YNHH) Women's Center and
Center for Women's Health and Midwifery (CWHM) postpartum patients ≤ 26 years of age who
deliver at YNHH York Street Campus (YSC) or Saint Raphael Campus (SRC).
potential to be an innovative intervention to improve HPV immunization rates. Following onset
of pregnancy, the postpartum period becomes the next available opportunity to immunize with
the HPV vaccine, which is safe in breastfeeding women. The benefits of such an intervention
include a focus on women engaged with the health care system who are often highly motivated
to invest in their personal health.
Specific Aims Aim 1: To evaluate receptivity and concerns of postpartum women with receiving
the HPV vaccine during the inpatient postpartum admission as part of the Inpatient Postpartum
HPV Immunization Quality Improvement Program (IPP-HPV).
Aim 2: To evaluate receptivity and concerns of healthcare providers with inpatient postpartum
HPV immunization as part of IPP-HPV and to identify facilitators of and barriers to its
implementation.
Aim 3: To assess the uptake and effectiveness of a Pilot Quality Improvement Program to
increase HPV vaccine uptake (IPP-HPV) for Yale New Haven Hospital (YNHH) Women's Center and
Center for Women's Health and Midwifery (CWHM) postpartum patients ≤ 26 years of age who
deliver at YNHH York Street Campus (YSC) or Saint Raphael Campus (SRC).
Inclusion Criteria:
- Women participating in the IPP-HPV Quality Improvement Program:
- Postpartum YNHH Women's Center and CWHM patients
- ≤ 26 years at time of delivery who deliver at YNHH YSC or SRC
- Have not already received 3 doses of the HPV vaccine at time of delivery
- Fluent in English or Spanish
- Able and willing to provide consent
AND
- Yale New Haven Hospital (YNHH) Women's Center and Center for Women's Health and
Midwifery (CWHM) postpartum patients
- ≤ 26 years of age
- Delivered at YNHH York Street Campus (YSC) or Saint Raphael Campus (SRC) in the first
year of the IPP-HPV program or in the one year preceding implementation of the program
OR
- YNHH inpatient postpartum nurses or Women's Center outpatient postpartum nurses or
inpatient or outpatient obstetric providers affiliated with the Women's Center or
Center for Women's Health and Midwifery
- Able and willing to provide consent
Exclusion Criteria:
We found this trial at
1
site
New Haven, Connecticut 06520
Principal Investigator: Sangini Sheth, MD
Phone: 203-737-8838
Click here to add this to my saved trials
